B. Riley lowered the firm’s price target on Kymera Therapeutics (KYMR) to $38 from $41 and keeps a Neutral rating on the shares following the Q1 report. The firm cites the TYK2 discontinuation for the target cut.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics: Innovative Approaches in Autoimmune Disease Treatment Drive Buy Rating
- Kymera Therapeutics price target lowered to $55 from $60 at BTIG
- Kymera Therapeutics price target lowered to $44 from $47 at BofA
- Kymera Therapeutics: Hold Rating Amid Uncertainty in KT-621 and Strategic Shifts
- Kymera Therapeutics: Promising Pipeline Developments and Strategic Decisions Support Buy Rating